Oveporexton vs Orexin-A
Written by Aaron CuhaReviewed Sep 2026
The short answer
The brain peptide and the approved drug that copies it. Oveporexton is a pill that switches on the orexin 2 switch, approved in August 2026 for narcolepsy type 1. Orexin-A is sold as a nose spray based on a monkey study, with only small human studies in narcolepsy where each person tried both.
- Oveporexton people
- 441
- Oveporexton nulls
- 0
- Orexin-A people
- 14
- Orexin-A nulls
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA approved 5 August 2026 (Orzeyful, NDA 220860) for narcolepsy type 1 in adults. It had orphan status, which is for drugs that treat rare diseases, and a priority (faster) FDA review. When the label was written, the DEA had not yet decided which controlled drug schedule it falls under.
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 14 people given it
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
OveporextonOveporexton (TAK-861), oral orexin receptor 2 selective agonist
A pill for narcolepsy type 1 that works on the brain's orexin wake system. It is not a peptide. The FDA approved it for adults on 5 August 2026. In two 12 week studies of 273 people, it kept people awake 14 to 20 minutes longer on a stay-awake test, while the dummy pill groups barely changed. Most people on it had trouble sleeping at night and needed to pee more often.
Column B
Orexin-AOrexin-A (hypocretin-1)
Orexin-A is the brain chemical that keeps you awake. It is sold as a nose spray for alertness, after a monkey study found a nose spray reversed the effects of lost sleep. The only human data are small studies in narcolepsy. Approved narcolepsy drugs are small-molecule pills, not this peptide.
Side by side, on the facts we can check
| What we compare | Oveporexton | Orexin-A |
|---|---|---|
| Category | Nootropic & CNS | Nootropic & CNS |
| FDA status | FDA approved 5 August 2026 (Orzeyful, NDA 220860) for narcolepsy type 1 in adults. It had orphan status, which is for drugs that treat rare diseases, and a priority (faster) FDA review. When the label was written, the DEA had not yet decided which controlled drug schedule it falls under. | Not approved |
| Half-life | Approximately 23.2 hours | Short |
| Molecular weight | 520.51 Da (small molecule, C23H25F5N2O4S) | 3,561.1 Da |
| How it works | In narcolepsy type 1, the brain cells that make orexin-A and orexin-B die off. So both orexin peptides run short, but the receptors they act on are still there. Oveporexton switches on one of those receptors, orexin receptor 2 (OX2R). That is the one most tied to staying awake. It restores the signal without replacing the peptide. The FDA label calls this the presumed way it works, not a proven one. That is the usual wording for this kind of drug. How the body handles it, from the label: blood levels peak after about 1.5 hours. It takes about 23.2 hours for the body to clear half of it. More than 96 percent rides bound to blood proteins. The liver breaks it down, mainly through an enzyme called CYP3A4, and 80.5 percent of a dose leaves in the stool. Drugs that strongly block CYP3A4 raise its levels about 7 fold, so they must not be taken with it. Drugs that block it moderately mean cutting the dose to 0.5 mg twice a day. The label says the bladder side effects fit with how the drug works, because orexin signals also help control the bladder. | It switches on two orexin receptors in the brain, which keep you awake and alert. |
| Studies in people | 6 | 1 |
| Evidence | Moderate: 6 completed trials, 441 people given it | Limited: 1 completed trial, 14 people given it |
| Legal status, US | FDA-approved, prescription only | Not approved; sold 'for research use only' |
Frequently asked questions
What is the difference between Oveporexton and Orexin-A?
Oveporexton: A pill for narcolepsy type 1 that works on the brain's orexin wake system. It is not a peptide. The FDA approved it for adults on 5 August 2026. In two 12 week studies of 273 people, it kept people awake 14 to 20 minutes longer on a stay-awake test, while the dummy pill groups barely changed. Most people on it had trouble sleeping at night and needed to pee more often. Orexin-A: Orexin-A is the brain chemical that keeps you awake. It is sold as a nose spray for alertness, after a monkey study found a nose spray reversed the effects of lost sleep. The only human data are small studies in narcolepsy. Approved narcolepsy drugs are small-molecule pills, not this peptide.
Which has stronger research evidence, Oveporexton or Orexin-A?
Each compound gets a band worked out from facts we counted, with the math shown. Oveporexton is Moderate (6 completed trials, 441 people given it). Orexin-A is Limited (1 completed trial, 14 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Oveporexton and Orexin-A FDA-approved?
Oveporexton: FDA approved 5 August 2026 (Orzeyful, NDA 220860) for narcolepsy type 1 in adults. It had orphan status, which is for drugs that treat rare diseases, and a priority (faster) FDA review. When the label was written, the DEA had not yet decided which controlled drug schedule it falls under.. Orexin-A: Not approved.
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.